SFM
GALT icon

Sphera Funds Management’s Galectin Therapeutics GALT Stock Holding History

Sphera Funds Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-205,000
Closed -$560K – 132
2015
Q2 		$560K Sell
205,000
-245,000
-54% -$739K 0.05% 124
2015
Q1 		$1.51M Buy
+450,000
New +$1.61M 0.16% 122

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sphera Funds Management's GALT Position: Q3 2015 in Review

Sphera Funds Management sold out of Galectin Therapeutics (GALT) in Q3 2015, closing a stake of 205,000 shares — an estimated $560K sold.

Sphera Funds Management first reported a position in GALT in Q1 2015 and held it in 2 quarters. The position peaked at $1.51M in Q1 2015. 51 funds tracked by Wall St. Rank hold GALT as of Q3 2015.

  • Sphera Funds Management reported no remaining Galectin Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Sphera Funds Management sold 205,000 Galectin Therapeutics shares in Q3 2015, an estimated $560K.
  • Sphera Funds Management first reported a position in Galectin Therapeutics in Q1 2015 and held it in 2 quarters.
  • Sphera Funds Management's Galectin Therapeutics position peaked at $1.51M in Q1 2015.
  • 51 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2015.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.